NASDAQ
23.03.26 | 18:11
13,130 US-Dollar
+2,98 % +0,380
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.03. | Cullinan Therapeutics: Q4 Earnings Insights | 3 | Benzinga.com | ||
| 10.03. | Stifel raises Cullinan Oncology stock price target on autoimmune progress | 1 | Investing.com | ||
| 10.03. | Cullinan Therapeutics GAAP EPS of -$0.77 misses by $0.05 | 1 | Seeking Alpha | ||
| 10.03. | Cullinan Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 10.03. | Cullinan Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| CULLINAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.03. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.02. | Guggenheim stuft Cullinan Oncology mit "Kaufen" ein und sieht 151 % Kurspotenzial | 10 | Investing.com Deutsch | ||
| 02.02. | Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target | 9 | Investing.com | ||
| 08.01. | Cullinan Therapeutics: Wichtige Studiendaten zu Autoimmun- und Krebstherapien für 2026 geplant | 4 | Investing.com Deutsch | ||
| 08.01. | Cullinan Therapeutics plans data readouts for key autoimmune programs | 2 | Investing.com | ||
| 08.01. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones | 677 | GlobeNewswire (Europe) | Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended... ► Artikel lesen | |
| 08.01. | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.12.25 | Cowen reiterates Buy rating on Cullinan Oncology stock after ASH data | 5 | Investing.com | ||
| 08.12.25 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting | 15 | GlobeNewswire (USA) | ||
| 08.12.25 | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.12.25 | Cullinan Therapeutics Announces Fast Track Designation For CLN-049 | 2 | RTTNews | ||
| 01.12.25 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia | 277 | GlobeNewswire (Europe) | Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients CAMBRIDGE, Mass., Dec. 01... ► Artikel lesen | |
| 26.11.25 | Cullinan Oncology stock price target raised to $36 at Jones Trading | 2 | Investing.com | ||
| 25.11.25 | Vielversprechende AML-Daten: BTIG erhöht Kursziel für Cullinan Oncology auf 38 US-Dollar | 12 | Investing.com Deutsch | ||
| 25.11.25 | Cullinan Oncology stock price target raised to $38 at BTIG on promising AML data | 2 | Investing.com |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIKING THERAPEUTICS | 28,745 | +2,75 % | Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics | ||
| BIOCRYST PHARMACEUTICALS | 8,622 | -0,35 % | BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz | ||
| IMMUNITYBIO | 7,860 | +5,96 % | Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX? | ||
| MICROBOT MEDICAL | 2,208 | +0,73 % | Microbot Medical Inc. - 8-K, Current Report | ||
| ATAIBECKLEY | 3,040 | 0,00 % | Milliardenmarkt Depression und PTBS: Wie Emyria und Atai die Psychiatrie-Ökonomie umkrempeln | ||
| CYTOKINETICS | 54,00 | +0,93 % | Mizuho raises Cytokinetics stock price target to $100 on IP extension | ||
| VOYAGER THERAPEUTICS | 3,246 | -0,31 % | Voyager Therapeutics erklärt 2026 zum "Jahr des Tau" | ||
| CAPRICOR | 25,100 | -1,18 % | CAPRICOR THERAPEUTICS, INC. - 10-K, Annual Report | ||
| ARCTURUS THERAPEUTICS | 6,725 | +1,28 % | Cathie Wood's ARK adds 10x Genomics stock, trims Arcturus | ||
| ZEVRA THERAPEUTICS | 8,150 | +1,88 % | Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million | BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare... ► Artikel lesen | |
| ABEONA THERAPEUTICS | 3,880 | +0,52 % | Abeona Therapeutics Inc.: Abeona Therapeutics Reports Full Year 2025 Financial Results and Corporate Updates | - First ZEVASKYN- commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 - - $191.4M in cash, cash equivalents and short-term investments as... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 15,100 | +2,03 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present New EKTERLY (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference | New interim data from the KONFIDENT-KID trial evaluating sebetralstat in children aged 2-11 accepted for late-breaking oral presentation KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,880 | -2,42 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 101,00 | +3,59 % | Palvella Therapeutics Inc.: Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services | Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (Nasdaq: KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting... ► Artikel lesen | |
| MARKER THERAPEUTICS | 1,010 | +2,02 % | Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results | Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature... ► Artikel lesen |
Das Unternehmen CULLINAN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,380 (+2,98 %) liegt der Kurs bei 13,130 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CULLINAN THERAPEUTICS INC finden Sie auf Wallstreet Online.